London open: Stocks gain as German GDP beats forecasts
14th Aug 2012 08:35
- German Q2 GDP above forecasts - Japanese stimulus could be on the agenda - Standard Life impresses as profits jump London's FTSE 100 advanced on Tuesday morning after German growth data beat expectations and investors hoped that policy-makers in Japan would step up to boost its economy. German e
Read moreLondon pre-open: Stocks to rise ahead of Eurozone GDP data
14th Aug 2012 07:17
City sources predict the FTSE 100 will open up 27 points from yesterday's close of 5,832, as expectations of further stimulus builds ahead of the release of Tuesday's Eurozone GDP and US retail sales data. Elsewhere, the minutes from the latest policy meeting of the Bank of Japan have revealed tha
Read moreAstra raises guidance after Pfizer OTC tie-up
14th Aug 2012 07:07
Anglo-Swedish drugs colossus AstraZeneca has raised earnings guidance a tad after signing a deal with US pharmaceuticals titan Pfizer. Astra's core earnings per share (EPS) target for 2012 has been increased to the range of $6.00 to $6.30 after the group revealed that Pfizer is to stump up for the
Read moreLondon close: Stocks finish higher after late rally
8th Aug 2012 16:45
After an early fall, London's benchmark index rallied in afternoon trade to finish a few points higher, extending gains from the previous three sessions. The last time the FTSE 100 finished higher was on April 2nd when it hit 5,875. "Stocks and other risky assets have traded higher since Friday. C
Read moreFTSE 100 movers: Standard Chartered heads back up
8th Aug 2012 15:36
Following a 16 per cent slump yesterday, emerging markets-focused bank Standard Chartered was leading the risers today. It was revealed yesterday that a US banking regulator accused it of collusion with the government of Iran to hide transactions from authorities. Rio Tinto, the mining and resourc
Read moreBroker tips: StanChart, Serco, AstraZeneca
8th Aug 2012 12:46
Credit Suisse has retained its cautious stance on under-fire lender Standard Chartered on the back of its struggles with US regulators in regards to its alleged dealings with the Iranian government. StanChart trades at 1.3 times full-year tangible net asset value for a 14-15% return on tangible equ
Read moreLondon midday: Sentiment dampened by BoE and Greece
8th Aug 2012 11:46
- ECB optimism fades - S and P cuts Greek outlook to 'negative' - BoE slashes growth forecast The Footsie remained firmly in the red on Wednesday morning as optimism earlier this week about the situation in Europe began to fade, particularly as Greece's credit rating outlook was lowered by Standard
Read moreBroker snap: Credit Suisse cuts sales and earnings estimates for Astra
8th Aug 2012 11:44
Jefferies has raised its target price for AstraZeneca from 2,975p to 3,100p, but has retained its 'hold' recommendation on the shares following 'another disappointing quarter'. According to the broker, AstraZeneca will likely continue to trade in a 'bond-like' fashion as investors await the appoint
Read moreWednesday broker round-up
8th Aug 2012 09:57
AstraZeneca: Jefferies raises target from 2,975p to 3,100p, hold rating kept. Avon Rubber: Investec reiterates hold rating and 315p target. BTG: Jefferies maintains hold rating and 410p target. Cobham: Jefferies reiterates buy recommendation and 230p target; Investec keeps sell rating and 200p ta
Read moreLondon open: Stocks slip on concerns over Greece
8th Aug 2012 09:02
- S and P cuts Greek outlook to 'negative' - Markets await BoE inflation report - StanChart rebounds after yesterday's sell-off UK stocks slipped in the opening hour on Wednesday, with the Footsie pulling back after a four-month high, after Greece's long-term sovereign rating outlook was cut by Sta
Read moreBTG takes a hit after Astra halts CytoFab development
8th Aug 2012 07:34
Specialist healthcare group BTG revealed on Tuesday that it will take a one-off charge after disappointing results from its 'CytoFab' study meant that further development of the drug has been halted. The group has received top-line data from an AstraZeneca study comparing the efficacy and safety of
Read moreBroker tips: IAG, AstraZeneca, Berkeley
6th Aug 2012 11:25
Credit Suisse has downgraded its recommendation for British Airways and Iberia owner International Consolidated Airlines Group, otherwise known as IAG, from 'outperform' to 'neutral' on the back of risks to 2013 consensus estimates. IAG reported a second-quarter loss of €4m last week and revealed g
Read moreBroker snap: Astra's a top pick in pharma sector, says UBS
6th Aug 2012 11:17
UBS has reviewed its coverage for the European pharmaceuticals sector, highlighting that, for that the first time in five to seven years, the 'generics cliff' is coming out of forecasts. Following second-quarter results from pharma majors which provide visibility on full US generics, UBS has reiter
Read moreMonday broker round-up
6th Aug 2012 08:26
AstraZeneca: UBS ups target from 3,500p to 3,600p, buy rating kept. Berkeley: Investec raises target from 1,500p to 1,560p, buy rating kept. Catlin: Nomura reiterates buy rating and 506p target. Centrica: Deutsche Bank downgrades to hold from buy, target cut from 365p to 320p. Falkland Oil and G
Read moreFriday broker round-up -UPDATE
27th Jul 2012 09:54
African Minerals: Goldman Sachs upgrades to buy. AG Barr: Investec reiterates buy recommendation and 485p target; Shore Capital downgrades to hold; N+1 Brewing downgrades to hold. AstraZeneca: Nordea downgrades to sell. Barclays: Investec maintains buy rating and 240p target. BG Group: UBS cuts
Read more